A Phase 1/2, Single-arm, Open-label Study of SGN-35 in Japanese Patients with relapsed/refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Trial Profile

A Phase 1/2, Single-arm, Open-label Study of SGN-35 in Japanese Patients with relapsed/refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2016

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 05 Nov 2015 New source identified and integrated (JapicCTI111650).
    • 25 Mar 2013 Results will be presented at a future medical conference, according to a Takeda media release.
    • 25 Mar 2013 Status changed from recruiting to completed, as reported in a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top